

Tapestri Single-Cell DNA MRD AML Panel

Advance your understanding of the clonal heterogeneity and evolution underpinning acute myeloid leukemia (AML) measurable residual disease (MRD) by targeting 41 genes with 323 amplicons for single-cell sequencing. Curated based on input from global key opinion leaders in acute myeloid leukemia and international guidelines such as the European LeukemiaNet (ELN) for AML MRD and the International Consensus Classification (ICC) for myeloid neoplasms, this panel covers the most commonly mutated hotspots in AML MRD. This panel has been verified in a wet lab to meet performance specifications.

Panel Specifications

Metric	Value
Number of genes	49*
Target type possible	SNVs, Indels, LOH, ITDs
Number of amplicons	323
Amplicon length	175-275 bp
Panel uniformity: % of amplicons >0.2x mean	≥90%
Panel Size	57.9 kb
% of amplicons with high GC Content	3.7%
Recommended number of reads per run	284 M

41-GENE MRD AML PANEL

ASXL1	CSF1R	GATA2	KMT2A	NPM1	SETBP1	TP53
BCOR	CYP4F3**	IDH1	KRAS	NRAS	SF3A1**	TRPC4**
BRAF	DNMT3A	IDH2	MEIS2**	PHF6	SF3B1	U2AF1
CALR	ETV6	IL6R**	MEN1	PPMID	SMC1A	UBA1**
CBFB	EZH2	IP6K1**	MYC	PTPNII	SRSF2	WT1
CBL	FLT3	JAK2	MYHII	RAD21	STAG2	ZEB2**
CHEK2	GATAI	KIT	NF1	RUNX1	TET2	ZRSR2

^{*}Includes 41 genes relevant to AML MRD and 8 germline gene targets for sample de-multiplexing.



^{**8} Gene targets for sample de-multiplexing